HC Wainwright Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI)
HC Wainwright reaffirmed their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a $95.00 price target on the stock. HC Wainwright also issued estimates for Denali Therapeutics’ Q2 2024 earnings at ($0.63) EPS, Q3 2024 earnings at ($0.63) EPS, […]
More Stories
Elevance Health, Inc. (NYSE:ELV) Short Interest Update
Elevance Health, Inc. (NYSE:ELV – Get Free Report) saw a large growth in short interest during the month of September....
Arm Holdings plc (NASDAQ:ARM) Given Average Recommendation of “Moderate Buy” by Analysts
Arm Holdings plc (NASDAQ:ARM – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the thirty...
AllianceBernstein Holding L.P. (NYSE:AB) Receives Consensus Rating of “Moderate Buy” from Brokerages
AllianceBernstein Holding L.P. (NYSE:AB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the five...
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Sees Significant Decrease in Short Interest
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) was the recipient of a large drop in short interest during the...
180 Life Sciences Corp. (NASDAQ:ATNFW) Short Interest Down 15.9% in September
180 Life Sciences Corp. (NASDAQ:ATNFW – Get Free Report) was the recipient of a large decline in short interest in...
DoubleLine Opportunistic Credit Fund (NYSE:DBL) Short Interest Update
DoubleLine Opportunistic Credit Fund (NYSE:DBL – Get Free Report) was the recipient of a large growth in short interest in...